S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
Log in
NASDAQ:ATRA

Atara Biotherapeutics Competitors

$16.07
+0.18 (+1.13 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.20
Now: $16.07
$16.25
50-Day Range
$15.89
MA: $18.41
$20.72
52-Week Range
$4.52
Now: $16.07
$28.20
Volume1.16 million shs
Average Volume883,680 shs
Market Capitalization$1.34 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.65

Competitors

Atara Biotherapeutics (NASDAQ:ATRA) Vs. ALLO, IOVA, CBPO, BEAM, SWTX, and RLAY

Should you be buying ATRA stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Atara Biotherapeutics, including Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), China Biologic Products (CBPO), Beam Therapeutics (BEAM), SpringWorks Therapeutics (SWTX), and Relay Therapeutics (RLAY).

Allogene Therapeutics (NASDAQ:ALLO) and Atara Biotherapeutics (NASDAQ:ATRA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Risk & Volatility

Allogene Therapeutics has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 2.65, indicating that its share price is 165% more volatile than the S&P 500.

Insider and Institutional Ownership

59.9% of Allogene Therapeutics shares are held by institutional investors. 31.3% of Allogene Therapeutics shares are held by company insiders. Comparatively, 4.3% of Atara Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Allogene Therapeutics and Atara Biotherapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allogene TherapeuticsN/AN/A$-184,590,000.00($1.83)-18.58
Atara BiotherapeuticsN/AN/A$-290,980,000.00($5.67)-2.83

Allogene Therapeutics is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Allogene Therapeutics and Atara Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Allogene TherapeuticsN/A-27.59%-24.97%
Atara BiotherapeuticsN/A-94.86%-82.17%

Analyst Ratings

This is a summary of recent recommendations and price targets for Allogene Therapeutics and Atara Biotherapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Allogene Therapeutics031302.81
Atara Biotherapeutics03702.70

Allogene Therapeutics presently has a consensus target price of $52.0833, suggesting a potential upside of 53.19%. Atara Biotherapeutics has a consensus target price of $35.8750, suggesting a potential upside of 123.24%. Given Atara Biotherapeutics' higher possible upside, analysts plainly believe Atara Biotherapeutics is more favorable than Allogene Therapeutics.

Summary

Allogene Therapeutics beats Atara Biotherapeutics on 8 of the 11 factors compared between the two stocks.

Iovance Biotherapeutics (NASDAQ:IOVA) and Atara Biotherapeutics (NASDAQ:ATRA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Profitability

This table compares Iovance Biotherapeutics and Atara Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Iovance BiotherapeuticsN/A-50.64%-45.64%
Atara BiotherapeuticsN/A-94.86%-82.17%

Analyst Ratings

This is a summary of recent recommendations and price targets for Iovance Biotherapeutics and Atara Biotherapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Iovance Biotherapeutics02802.80
Atara Biotherapeutics03702.70

Iovance Biotherapeutics presently has a consensus target price of $50.10, suggesting a potential upside of 54.82%. Atara Biotherapeutics has a consensus target price of $35.8750, suggesting a potential upside of 123.24%. Given Atara Biotherapeutics' higher possible upside, analysts plainly believe Atara Biotherapeutics is more favorable than Iovance Biotherapeutics.

Insider and Institutional Ownership

94.6% of Iovance Biotherapeutics shares are held by institutional investors. 9.9% of Iovance Biotherapeutics shares are held by company insiders. Comparatively, 4.3% of Atara Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Iovance Biotherapeutics and Atara Biotherapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Iovance BiotherapeuticsN/AN/A$-197,560,000.00($1.59)-20.35
Atara BiotherapeuticsN/AN/A$-290,980,000.00($5.67)-2.83

Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Iovance Biotherapeutics has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 2.65, indicating that its share price is 165% more volatile than the S&P 500.

Summary

Iovance Biotherapeutics beats Atara Biotherapeutics on 8 of the 11 factors compared between the two stocks.

Atara Biotherapeutics (NASDAQ:ATRA) and China Biologic Products (NASDAQ:CBPO) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations.

Profitability

This table compares Atara Biotherapeutics and China Biologic Products' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atara BiotherapeuticsN/A-94.86%-82.17%
China Biologic Products27.43%8.32%7.64%

Analyst Recommendations

This is a summary of recent ratings and target prices for Atara Biotherapeutics and China Biologic Products, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atara Biotherapeutics03702.70
China Biologic Products0000N/A

Atara Biotherapeutics presently has a consensus target price of $35.8750, suggesting a potential upside of 123.24%. Given Atara Biotherapeutics' higher possible upside, analysts clearly believe Atara Biotherapeutics is more favorable than China Biologic Products.

Insider & Institutional Ownership

34.8% of China Biologic Products shares are held by institutional investors. 4.3% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 2.7% of China Biologic Products shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Atara Biotherapeutics and China Biologic Products' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atara BiotherapeuticsN/AN/A$-290,980,000.00($5.67)-2.83
China Biologic Products$503.70 million9.20$138.81 million$4.2827.51

China Biologic Products has higher revenue and earnings than Atara Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than China Biologic Products, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Atara Biotherapeutics has a beta of 2.65, indicating that its stock price is 165% more volatile than the S&P 500. Comparatively, China Biologic Products has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500.

Summary

China Biologic Products beats Atara Biotherapeutics on 8 of the 12 factors compared between the two stocks.

Atara Biotherapeutics (NASDAQ:ATRA) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations.

Profitability

This table compares Atara Biotherapeutics and Beam Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atara BiotherapeuticsN/A-94.86%-82.17%
Beam Therapeutics-529,075.00%-103.41%-48.05%

Analyst Recommendations

This is a summary of recent ratings and target prices for Atara Biotherapeutics and Beam Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atara Biotherapeutics03702.70
Beam Therapeutics03302.50

Atara Biotherapeutics presently has a consensus target price of $35.8750, suggesting a potential upside of 123.24%. Beam Therapeutics has a consensus target price of $96.00, suggesting a potential upside of 32.23%. Given Atara Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Atara Biotherapeutics is more favorable than Beam Therapeutics.

Insider & Institutional Ownership

49.8% of Beam Therapeutics shares are held by institutional investors. 4.3% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 0.7% of Beam Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Atara Biotherapeutics and Beam Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atara BiotherapeuticsN/AN/A$-290,980,000.00($5.67)-2.83
Beam Therapeutics$20,000.00210,416.58$-78,330,000.00($14.05)-5.17

Beam Therapeutics has higher revenue and earnings than Atara Biotherapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Atara Biotherapeutics beats Beam Therapeutics on 8 of the 12 factors compared between the two stocks.

Atara Biotherapeutics (NASDAQ:ATRA) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations.

Profitability

This table compares Atara Biotherapeutics and SpringWorks Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atara BiotherapeuticsN/A-94.86%-82.17%
SpringWorks TherapeuticsN/A-24.48%-23.58%

Analyst Recommendations

This is a summary of recent ratings and target prices for Atara Biotherapeutics and SpringWorks Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atara Biotherapeutics03702.70
SpringWorks Therapeutics00303.00

Atara Biotherapeutics presently has a consensus target price of $35.8750, suggesting a potential upside of 123.24%. SpringWorks Therapeutics has a consensus target price of $91.00, suggesting a potential upside of 22.31%. Given Atara Biotherapeutics' higher possible upside, analysts clearly believe Atara Biotherapeutics is more favorable than SpringWorks Therapeutics.

Insider & Institutional Ownership

76.3% of SpringWorks Therapeutics shares are held by institutional investors. 4.3% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 51.2% of SpringWorks Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Atara Biotherapeutics and SpringWorks Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atara BiotherapeuticsN/AN/A$-290,980,000.00($5.67)-2.83
SpringWorks TherapeuticsN/AN/A$-58,310,000.00($3.55)-20.96

SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Atara Biotherapeutics has a beta of 2.65, indicating that its stock price is 165% more volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

Summary

SpringWorks Therapeutics beats Atara Biotherapeutics on 7 of the 11 factors compared between the two stocks.

Atara Biotherapeutics (NASDAQ:ATRA) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations.

Profitability

This table compares Atara Biotherapeutics and Relay Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atara BiotherapeuticsN/A-94.86%-82.17%
Relay TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and target prices for Atara Biotherapeutics and Relay Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atara Biotherapeutics03702.70
Relay Therapeutics01502.83

Atara Biotherapeutics presently has a consensus target price of $35.8750, suggesting a potential upside of 123.24%. Relay Therapeutics has a consensus target price of $57.40, suggesting a potential upside of 53.52%. Given Atara Biotherapeutics' higher possible upside, analysts clearly believe Atara Biotherapeutics is more favorable than Relay Therapeutics.

Insider & Institutional Ownership

98.4% of Relay Therapeutics shares are held by institutional investors. 4.3% of Atara Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Atara Biotherapeutics and Relay Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atara BiotherapeuticsN/AN/A$-290,980,000.00($5.67)-2.83
Relay TherapeuticsN/AN/AN/AN/AN/A

Summary

Relay Therapeutics beats Atara Biotherapeutics on 4 of the 7 factors compared between the two stocks.


Atara Biotherapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$34.00+4.6%$4.78 billionN/A-15.96Analyst Revision
Gap Up
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$32.36+1.8%$4.76 billionN/A-16.85Analyst Upgrade
High Trading Volume
China Biologic Products logo
CBPO
China Biologic Products
0.8$117.76+0.3%$4.64 billion$503.70 million32.89Upcoming Earnings
Increase in Short Interest
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$72.60+1.2%$4.21 billion$20,000.00-5.17Gap Down
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.6$74.40+6.9%$3.64 billionN/A-42.76Analyst Report
High Trading Volume
Gap Up
RLAY
Relay Therapeutics
1.8$37.39+7.0%$3.36 billionN/A0.00Gap Down
Revolution Medicines logo
RVMD
Revolution Medicines
1.5$45.50+6.7%$3.02 billion$50.04 million0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
NantKwest logo
NK
NantKwest
1.1$26.80+3.9%$2.92 billion$40,000.00-37.75Decrease in Short Interest
Gap Down
Editas Medicine logo
EDIT
Editas Medicine
1.4$41.63+3.1%$2.80 billion$20.53 million-23.93Analyst Report
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$63.37+3.7%$2.79 billion$125.57 million-37.06Earnings Announcement
Analyst Report
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$8.88+0.8%$2.49 billion$31.43 million-6.08Analyst Revision
News Coverage
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$48.18+4.8%$2.14 billionN/A0.00Upcoming Earnings
News Coverage
Gap Up
AlloVir logo
ALVR
AlloVir
1.4$30.52+13.1%$1.99 billionN/A0.00Insider Selling
High Trading Volume
Gap Down
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$11.15+2.1%$1.98 billion$48.83 million-14.67
Vericel logo
VCEL
Vericel
1.5$42.51+4.9%$1.95 billion$117.85 million-4,251,000.00Analyst Report
Analyst Revision
Gap Up
bluebird bio logo
BLUE
bluebird bio
1.8$28.68+2.6%$1.93 billion$44.67 million-2.61Analyst Report
Gap Up
Scholar Rock logo
SRRK
Scholar Rock
1.3$53.53+5.5%$1.80 billion$20.49 million-22.21Upcoming Earnings
News Coverage
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$41.63+6.1%$1.79 billionN/A0.00Upcoming Earnings
News Coverage
Gap Up
Translate Bio logo
TBIO
Translate Bio
1.4$22.23+4.2%$1.65 billion$7.80 million-20.78Upcoming Earnings
Analyst Revision
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.74+2.6%$1.64 billionN/A-5.91Analyst Report
Unusual Options Activity
Analyst Revision
Gap Down
Replimune Group logo
REPL
Replimune Group
1.5$35.31+8.5%$1.64 billionN/A-19.95High Trading Volume
News Coverage
Gap Up
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.36+1.1%$1.63 billion$102.43 million-18.93Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$72.74+1.5%$1.61 billionN/A-49.15Earnings Announcement
Analyst Upgrade
Analyst Revision
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.93+1.8%$1.49 billion$35.23 million-16.10Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.87+1.3%$1.39 billion$100.56 million0.00Upcoming Earnings
Decrease in Short Interest
News Coverage
Alector logo
ALEC
Alector
1.3$17.07+4.8%$1.36 billion$21.22 million-7.65Analyst Upgrade
News Coverage
Gap Up
Immunovant logo
IMVT
Immunovant
1.8$13.51+3.2%$1.32 billionN/A-10.47Increase in Short Interest
PCVX
Vaxcyte
1.8$23.76+0.6%$1.21 billionN/A0.00Upcoming Earnings
Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.83+3.7%$1.15 billion$356.07 million7.76Analyst Report
Gap Up
Cortexyme logo
CRTX
Cortexyme
1.3$37.99+4.3%$1.12 billionN/A-15.83Earnings Announcement
Gap Up
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$29.36+20.3%$1.11 billionN/A0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$11.12+1.4%$1.09 billion$250,000.00-8.76Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Mesoblast logo
MESO
Mesoblast
1.4$9.17+0.1%$1.08 billion$32.16 million-10.42Earnings Announcement
Analyst Upgrade
Analyst Revision
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.3$12.56+17.2%$1.02 billionN/A-5.87News Coverage
Gap Up
Inhibrx logo
INBX
Inhibrx
1.7$26.39+0.6%$995.22 millionN/A0.00Upcoming Earnings
Gap Down
Passage Bio logo
PASG
Passage Bio
1.9$19.83+2.0%$910.53 millionN/A0.00Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Gap Up
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.10+5.5%$906.51 millionN/A-4.15News Coverage
Gap Up
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$18.75+2.7%$879.69 million$69.89 million-4.47Gap Down
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$22.41+3.9%$854.22 millionN/A0.00Gap Up
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.80+3.0%$828.87 millionN/A-10.25
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$21.11+3.9%$814.93 million$42.74 million-234.56Gap Up
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.13+2.3%$794.02 million$1.12 million-5.18Analyst Upgrade
Gap Up
Cellectis logo
CLLS
Cellectis
1.3$18.19+6.2%$772.82 million$22.99 million-9.68Earnings Announcement
News Coverage
Gap Down
Vaxart logo
VXRT
Vaxart
1.3$6.02+1.7%$708.96 million$9.86 million-10.20Analyst Report
Analyst Revision
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.76+1.5%$657.51 million$2.51 million-4.10Earnings Announcement
Analyst Report
Increase in Short Interest
Analyst Revision
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$31.54+2.9%$640.89 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.18+0.6%$623.06 millionN/A0.00Upcoming Earnings
Decrease in Short Interest
News Coverage
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.20+1.3%$608.48 million$150.05 million-2.94
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.50+4.2%$603.52 million$22.24 million-5.72Upcoming Earnings
Analyst Report
Gap Up
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.21+3.6%$572.36 million$14.75 million-2.24Upcoming Earnings
Gap Up
This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.